Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016

Eli Lilly recorded $7.69bn in rebates and discounts in the US in 2016 as pharmacy benefit managers demanded greater price concessions in crowded categories like diabetes.

Eli Lilly & Co.’s pharmaceutical rebates and discounts to US payers in the commercial and government-sponsored insurance markets rose by nearly 30% in 2016 as the company fought to gain favorable access for its diabetes drugs and other products.

Rebate and discount payments totaled $7.69bn in 2016, compared with $5.93bn the year before, the company disclosed in its recently-released...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access